Simvastatin and Rifaximin in Decompensated Cirrhosis
Authors:
Top Cited Papers
- 11 March 2025
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 333 (10) , 864
Abstract
Importance: There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis.Objective: To assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis.Design, Setting, and Participants: Double-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022.Interventions: Patients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratified according to Child-Pugh class B or C.Main Outcomes and Measures: The primary end point was incidence of severe complications of liver cirrhosis associated with organ failure meeting criteria for acute-on-chronic liver failure. Secondary outcomes included transplant or death and a composite end point of complications of cirrhosis (ascites, hepatic encephalopathy, variceal bleeding, acute kidney injury, and infection).Results: Among the 237 participants randomized (Child-Pugh class B: n = 194; Child-Pugh class C: n = 43), 72% were male and the mean age was 57 years. There were no differences between the 2 groups in terms of development of acute-on-chronic liver failure (21 [17.9%] vs 17 [14.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 1.23; 95% CI, 0.65-2.34; P = .52); transplant or death (22 [18.8%] vs 29 [24.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.75; 95% CI, 0.43-1.32; P = .32); or development of complications of cirrhosis (50 [42.7%] vs 55 [45.8%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.93; 95% CI, 0.63-1.36; P = .70). Incidence of adverse events was similar in both groups (426 vs 419; P = .59), but 3 patients in the treatment group (2.6%) developed rhabdomyolysis.Conclusions and Relevance: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.Trial Registration: ClinicalTrials.gov Identifier: NCT03780673Keywords
This publication has 39 references indexed in Scilit:
- The Use of Rifaximin in Patients With CirrhosisHepatology, 2021
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive SummaryJACC, 2019
- Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A population‐based studyHepatology, 2017
- Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trialDigestive and Liver Disease, 2015
- Statin Use in Patients with Cirrhosis: A Retrospective Cohort StudyDigestive Diseases and Sciences, 2014
- Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and AscitesClinical Gastroenterology and Hepatology, 2012
- Time Course of C-Reactive Protein Reduction With Simvastatin Therapy in Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophagesJournal of Biomedical Science, 2003
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973